Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT01000350

Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)

The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Postural Tachycardia Syndrome Arrhythmias, Cardiac Autonomic Nervous System Diseases Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases Nervous System Diseases Neurologic Manifestations Orthostatic Intolerance Pathologic Processes Pathological Conditions, Signs and Symptoms Postural Orthostatic Tachycardia Syndrome Primary Dysautonomias Signs and Symptoms Tachycardia

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University

Nashville, Tennessee, 37232-2195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet diagnostic criteria of Postural Tachycardia Syndrome (POTS) 28
  • Age between 18-65 years
  • Male and female are eligible (although the majority of POTS patients are female).
  • Able and willing to provide informed consent

Exclusion criteria

  • Presence of medical conditions that can explain postural tachycardia (e.g., acute dehydration, medications)
  • Pregnancy
  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol.
  • Patients who are bedridden or chair-ridden

Treatment and study plan

Saline

Drug

IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study

Other names: Normal Saline, 0.9% saline

Placebo

Other

Placebo x1 lactose tablet

Primary outcomes

  1. Difference in VO2max between saline day and placebo day

    Time frame: Within 2 week

    VO2max will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.

Secondary outcomes

  1. Exercise capacity/Maximal Load (Watts) during peak VO2

    Time frame: Less than 2 weeks

    Maximal exercise load will be measured hours after saline and after placebo. The 2 interventions will be less than 2 weeks apart.

  2. Cardiac output between exercise tests (inert gas rebreathing technique)

    Time frame: 2-10 Days between exercise tests

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Official study title

Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance

Important dates

Study start
2009
Primary completion
2028
Study completion
2028
First posted
Oct 23, 2009
Registry last updated
Oct 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.